MSJ917925_supplemental_table_1 – Supplemental material for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP) Helmut Butzkueven Maria Trojano Ludwig Kappos Tim Spelman Heinz Wiendl Karen Rosales Ray Su Stephanie Licata Pei-Ran Ho Nolan Campbell 10.25384/SAGE.12311066.v1 https://sage.figshare.com/articles/journal_contribution/MSJ917925_supplemental_table_1_Supplemental_material_for_Clinical_outcomes_in_patients_who_discontinue_natalizumab_therapy_after_2_years_in_the_Tysabri_sup_sup_Observational_Program_TOP_/12311066 <p>Supplemental material, MSJ917925_supplemental_table_1 for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP) by Helmut Butzkueven, Maria Trojano, Ludwig Kappos, Tim Spelman, Heinz Wiendl, Karen Rosales, Ray Su, Stephanie Licata, Pei-Ran Ho and Nolan Campbell in Multiple Sclerosis Journal</p> 2020-05-15 12:10:40 Discontinuation disease-modifying therapy multiple sclerosis natalizumab observational study relapse